New schizophrenia shot could offer cheaper alternative to Brand-Name drug
NCT ID NCT07493551
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new generic version of a 3-month schizophrenia injection works the same as the brand-name drug Invega Trinza. About 260 Chinese adults with stable schizophrenia will receive multiple doses of either the test or reference drug. The goal is to see if the two formulations reach similar drug levels in the blood and have similar safety profiles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
paliperidone palmitate injection (3-month formulation)
What this could lead to
If successful, this could provide a more affordable, equally effective long-acting treatment option for schizophrenia patients in China.
What could go wrong
This is a bioequivalence study, not a test of new efficacy or safety. It only compares two formulations in a specific population, so results may not apply broadly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Anding Hospital Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100120, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact